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Pathogenesis of dengue involves suppression of immune system leading to development of characteristic presentation of hae-
matological picture of thrombocytopenia and leucopenia. Sometimes, this suppression in immune response is responsible for
deterioration in clinical status of the patient in spite of all speciﬁc and supportive therapy. Certain drugs like steroids are used
for rescue therapy in conditions like sepsis. We present a novel use of ﬁlgrastim as a rescue therapy in a patient with dengue
hemorrhagic fever (DHF) with acute respiratory distress syndrome (ARDS), myocarditis, and febrile neutropenia and not re-
sponding to standard management.
1.Introduction
The management of dengue hemorrhagic shock with ongo-
ing deterioration in clinical status like multiorgan failure is
a real challenge for an intensivist. Pathophysiologic mech-
anisms have not been well described in dengue, although
immune suppression has been cited leading to thrombo-
cytopenia and leucopenia [1, 2]. Filgrastim, a granulocyte
colony-stimulatingfactor(G-CSF)hasbeenusedasadjuvant
therapy in patients of pneumonia with sepsis [3]. We hereby
report a case of dengue hemorrhagic fever (DHF) with
acute respiratory distress syndrome (ARDS), myocarditis,
and febrile neutropenia which improved with the usage of
ﬁlgrastim as a rescue therapy.
2.CaseReport
A 23-year-old female presented to medical clinics with
history of cough, sore throat, and high grade fever for last
7 days. The fever was high grade (101–103◦F) and was not
associatedwithchillsandrigor.Onreviewingthehistory,she
did not have any other comorbid illness. On investigations,
she was found to have positive serology for dengue and her
platelet count was 20,000/mm3. She was admited in the
medical ward, and 6 hours later her blood pressure dropped
to 82/42mmHg. After adequately resuscitating her with
intravenous ﬂuids, she was started on dopamine infusion
a n dt i t r a t e da t5µg/kg/min to maintain her blood pressure
at 106/62mmHg. She was shifted to intensive care unit
for further management. The patient’s respiratory rate in-
creased to 35/minute. Her chest X-ray revealed bilateral
pulmonary inﬁltrates suggestive of acute respiratory distress
syndrome.Heroxygensaturation(SpO2)was88%onoxygen
by face mask. Arterial blood gas analysis revealed a paO2 of
55mmHg. She was given a trial of noninvasive ventilation
but she could not maintain oxygen saturation (SpO2—84–
86%). She was tracheally intubated and started on mechan-
ical ventilation. Her repeat platelet count was 12,000/mm3.
Other laboratory investigations revealed haemoglobin
11.8g/dL, total leucocyte count (TLC): 10,800/mm3, dif-
ferential leucocyte counts: neutrophil: 85%, lymphocytes:
13%, sodium: 144 mg/L, potassium: 3.6mg/L, blood urea:2 Case Reports in Anesthesiology
48mg/dL, serum creatinine: 1.1mg/dL and total bilirubin:
0.9 mg/dL. Her international normalized ratio (INR) was
1.2, d-dimer and ﬁbrin degradation products were negative.
She was transfused with 4 units of platelet concentrate.
Her condition further deteriorated requiring escalation of
inotropicsupporttonoradrenaline0.4µg/kg/min,dopamine
10µg/kg/min. A ﬁnal diagnosis of acute respiratory distress
syndrome (ARDS) and dengue hemorrhagic shock was
made. Viral markers for HCV, HBV, and HIV were negative.
Electrocardiogram revealed sinus tachycardia with peaked P
wave. Echocardiography revealed ejection fraction of 45%,
mild left ventricular global hypokinesia, mild tricuspid
regurgitation with a pressure gradient of 30mmHg. Serum
cardiac enzymes: creatine phosphokinase MB levels were
116I.U/L (normal up to 20) and lactic acid dehydrogenase
was 2489u/L (normal up to 260). Tropnin-T was negative.
An additional diagnosis of viral myocarditis was made.
Dobutamine was started and noradrenaline was tapered oﬀ
and subsequently stopped. Patient required an FiO2 of 0.8–1
to maintain of SpO2 > 90%. So, patient received intermittent
prone ventilation to keep FiO2 less than 0.6% for ﬁrst three
days (6–8 hours each day). Central venous pressure (CVP)
o f6t o8c mo fH 2O was maintained as further increase in
CVP manifested in pulmonary edema twice. Patient had
an episode of pulseless ventricular tachycardia which was
managed with electrical therapy once and subsequently
required 300mg bolus amiodarone followed by 45mg/hr
infusion. By third day, patient platelet count improved and
reached 66,000 and then 1,20,000/mm3 by 5th day. But a
continuous falling trend of leucocyte count was observed
from 9800 on ﬁrst day to 800/mm3 by 5th day. She also had
persistent fever of 102 to 104◦F, despite being given coverage
of broad-spectrum antibiotics and persistently negative
cultures report (blood, urine, tracheal aspirate, CSF). When
her leucocyte count dropped to less than 4000, intravenous
hydrocortisone 50mg BD was started. Despite this her
leucocyte count dropped to 800/mm3 with diﬀerential count
of polymorpholeucocytes of 46% and fever persisted. On
6th day, after written and informed consent from patients
guardian, a trial of intravenous ﬁlgrastim 150µgw a sg i v e n
for two days. Her leucocyte counts improved to 9000/mm3
on seventh day and 15,000/mm3 on eighth day. Platelet
count was 1.5 × 103/mm3. Clinically, her fever also subsided.
She was weaned oﬀ from ventilator and inotropic support
within next three days. Patient shifted to high dependency
unit on 9th day. She was discharged uneventfully on 15th
day with advice to follow-up in medical clinics.
3. Discussion
Our patient has persistent deterioration in clinical status
and did not respond to routine management including
antibiotics and mechanical ventilation support. She required
inotropic support and had features suggestive of sepsis.
Filgrastim has been mentioned as rescue drug in certain
high risk patients with established febrile neutropenia seen
in pneumonia, hypotension, sepsis syndrome, multiorgan
dysfunction, fungal infection, uncontrolled primary disease,
or profound neutropenia (absolute neutrophil count (ANC)
<100/mcL) [4]. Filgrastim is a hematopoietic hormone that
promotes the growth and maturation of myeloid cells, and
particularly, the proliferation and diﬀerentiation of neutro-
phils [5, 6]. The usual dose of ﬁlgrastim in cancer chem-
otherapy is 5µg/kg/day and the duration depend on indica-
tion. But no recommendation has been made in favour or
against any regimen [4]. In the absence of recommendation
regarding the dose and duration of the ﬁlgrastim in such
patients, we started the drug at a lower dose and duration
was guided by the leucocyte response. After 2 days, when we
achieved acceptable neutrophil count and clinical condition
also showed an improvement, we decided to stop the drug
further. Though we were apprehensive about the deteriora-
tion in lung condition as neutrophils has been proposed to
be an important pathological mediator for initiating ARDS,
ﬁlgrastim has been safely used in ARDS and MODS [3].
Filgrastim use decreased incidence of DIC and ARDS in
adults with community-acquired pneumonia and reduced
mortality from 30% to 10% in neonatal sepsis [7, 8].
There is evidence of immune suppression together with
activation of immune-mediated destruction of target cells in
DHF [1, 2]. In our case ﬁlgrastim use resulted in resolution
of patient’s fever and improvement of her clinical condition
probably by reversing bone marrow depression and in-
creasing leucocyte and lymphocyte count, thus enabling
her to mount an immune response and leading thereby to
resolution of fever. Noninfectious causes of fever including
antibiotic-induced fever were ruled out as our patient tem-
perature was persistently ≥102◦F, and febrile neutropenia is
an indication to continue with broad-spectrum antibiotics.
Antibiotic-induced granulocytopenia was ruled out because
increased ratio of polymorphonuclear leucocytes over lym-
phocytes as seen in sepsis was present in contrast to an-
tibiotic-induced granulocytopenia where lymphocytes are
only remaining markers of leuckocytes [9].
There is an ongoing debate over use of ﬁlgrastim as an
adjunct to antibiotic therapy because of its high cost and
considering its unconvincing outcomes. Safety proﬁle and
low-dose use of ﬁlgrastim for shorter duration resulted in
improved outcome of our case. Further randomized con-
trolled trials are needed in scenario of febrile neutropenia to
study adjunctive role of low-dose ﬁlgrastim as rescue therapy
with antibiotics especially in dengue syndrome where one of
the target organ is haematopoietic system.
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